| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Changes in fair value of embedded derivative instrument | - | - | 210 | 429 |
| Other non-cash items, net | -631 | -348 | - | - |
| Accounts receivable, net | 42,050 | 33,621 | 12,349 | 33,133 |
| Inventories | 7,324 | 1,433 | 1,951 | 135 |
| Prepaid expenses and other current assets | 742 | -1,018 | 3,282 | 882 |
| Accounts payable | -8,425 | 863 | 309 | 2,334 |
| Accrued liabilities | 26,592 | 21,018 | -214 | 18,850 |
| Operating lease liabilities | -554 | -404 | -200 | -547 |
| Net cash used in operating activities | -31,810 | -30,056 | -30,380 | -111,410 |
| Purchases of marketable securities | 157,806 | 89,262 | 56,110 | 237,421 |
| Proceeds from maturities of marketable securities | 172,418 | 129,121 | 68,468 | 231,507 |
| Milestone payment for intangible asset | 10,000 | 10,000 | - | - |
| Purchases of property and equipment | 686 | 686 | 608 | 143 |
| Net cash provided by (used in) investing activities | 3,926 | 29,173 | 11,750 | -6,057 |
| Proceeds from issuance of common stock upon exercise of stock options | 1,932 | 456 | 395 | 1,282 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 1,319 | 1,319 | - | 649 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 | 0 | 161,682 |
| Net cash provided by financing activities | 3,251 | 1,775 | 395 | 163,613 |
| Effect of exchange rate changes on cash | 109 | 204 | 4 | -1 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -24,524 | 1,096 | -18,231 | 46,145 |
| Cash and cash equivalents at beginning of period | 71,952 | 71,952 | 71,952 | 89,323 |
| Cash and cash equivalents at end of period | 47,428 | 73,048 | 53,721 | 135,468 |
Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT)